Intra-Cellular Therapies Inc.

Historical 13F Holders

Symbol
ITCI
CUSIP
46116X101
All holders as of
Q2 2026
Type
Equity
Class
COM
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 46116X101 since 12/18/2024, largest first.

Filer % of Class Filed
Under 5%, checked the "5 percent or less" box, or amended by a later filing (2)
FMR LLC 13G/A
2.5% 2/7/2025
Event 1/31/2025
JPMorgan Chase & Co 13G/A 0% 6/5/2025
Event 5/30/2025

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2026 Q2 1 1.00 $2.54 k
2026 Q1 1 1.00 $2.54 k
2025 Q4 1 1.00 $2.54 k
2025 Q3 1 1.00 $2.54 k
2025 Q2 4 52.8 k $4.15 M
2025 Q1 435 103 M $13.6 B
2024 Q4 408 96.8 M $8.08 B
2024 Q3 377 103 M $7.52 B
2024 Q2 401 102 M $6.96 B
2024 Q1 387 93.0 M $6.43 B
2023 Q4 364 94.2 M $6.75 B
2023 Q3 313 87.9 M $4.58 B
2023 Q2 307 85.7 M $5.43 B
2023 Q1 301 84.6 M $4.59 B
2022 Q4 303 86.3 M $4.57 B
2022 Q3 296 84.0 M $3.91 B
2022 Q2 282 81.5 M $4.65 B
2022 Q1 263 80.8 M $4.96 B
2021 Q4 239 69.2 M $3.61 B
2021 Q3 198 68.6 M $2.56 B
2021 Q2 206 67.0 M $2.74 B
2021 Q1 187 68.0 M $2.30 B
2020 Q4 207 69.8 M $2.22 B
2020 Q3 201 63.8 M $1.63 B
2020 Q2 183 48.8 M $1.25 B
2020 Q1 157 48.0 M $755 M
2019 Q4 177 38.9 M $1.33 B
2019 Q3 157 40.2 M $300 M
2019 Q2 166 40.2 M $521 M
2019 Q1 150 38.5 M $469 M
2018 Q4 153 38.4 M $438 M
2018 Q3 155 38.8 M $843 M
2018 Q2 149 39.8 M $704 M
2018 Q1 146 40.2 M $846 M
2017 Q4 146 38.2 M $553 M
2017 Q3 158 40.8 M $643 M
2017 Q2 110 31.0 M $385 M
2017 Q1 131 29.8 M $483 M
2016 Q4 139 30.6 M $462 M
2016 Q3 154 27.9 M $425 M
2016 Q2 150 30.6 M $1.20 B
2016 Q1 132 29.4 M $818 M
2015 Q4 143 28.6 M $1.54 B
2015 Q3 138 27.9 M $1.12 B
2015 Q2 95 18.1 M $578 M
2015 Q1 74 17.0 M $405 M
2014 Q4 47 12.2 M $216 M
2014 Q3 50 12.1 M $166 M
2014 Q2 56 12.2 M $205 M
2014 Q1 35 11.0 M $201 M